NGcGM3 ganglioside: a privileged target for cancer vaccines.
Active specific immunotherapy is a promising field in cancer research. N-glycolyl (NGc) gangliosides, and particularly NGcGM3, have received attention as a privileged target for cancer therapy. Many clinical trials have been performed with the anti-NGc-containing gangliosides anti-idiotype monoclonal antibody racotumomab (formerly known as 1E10) and the conjugated NGcGM3/VSSP vaccine for immunotherapy of melanoma, breast, and lung cancer. The present paper examines the role of NGc-gangliosides in tumor biology as well as the available preclinical and clinical data on these vaccine products. A brief discussion on the relevance of prioritization of cancer antigens in vaccine development is also included.
Vaccine Department, Center of Molecular Immunology, Havana, Cuba.
Luis E
LE
Fernandez
Mariano R
MR
Gabri
Marcelo D
MD
Guthmann
Roberto E
RE
Gomez
Silvia
S
Gold
Leonardo
L
Fainboim
Daniel E
DE
Gomez
Daniel F
DF
Alonso
D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines; D002986:Clinical Trials as Topic; D005679:G(M3) Ganglioside / Q000031:analogs & derivatives* / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000276:immunology* / Q000628:therapy
D000888:Antibodies, Anti-Idiotypic; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D005679:G(M3) Ganglioside; C044298:N-glycolylneuraminyllactosylceramide